This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| 5-Amino-1MQ | Survodutide | |
|---|---|---|
| Highest evidence tier on the page | E4 Preclinical only Animal or in vitro work. Not demonstrated in humans. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not approved for human use | In clinical development, not approved |
| Research area | Metabolic and incretin | Metabolic and incretin |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C10H11N2+ (free cation); C10H11ClN2 (chloride salt) | C192H289N47O61, from a chemical supplier data sheet only, not confirmed against a peer-reviewed or regulatory source |
| Molar mass | 159.21 g/mol, calculated for the free cation; 194.66 g/mol, calculated for the chloride salt | 4231.7, from a chemical supplier data sheet only, not confirmed against a peer-reviewed or regulatory source |
| CAS number | 685079-15-6 (free cation); no independently confirmed CAS number exists for the chloride salt | 2805997-46-8, from vendor catalogues, and salt-form assignments in those catalogues are not reliable |
| Registered trials on this site | None linked yet | 14 in the tracker |
| What is not known | Everything about this compound in a human being. No interventional trial, observational study or published case report of 5-Amino-1MQ administered to a person exists, so whether it has any effect, at any dose, with any safety profile, in a human is entirely unanswered. Any human... | Whether survodutide raises energy expenditure in a human being. That is the central mechanistic claim made for the compound, it rests on rodent indirect calorimetry that reached significance at one dose on two days with no change in core temperature or activity, and it has... |
| Furthest registered phase | Not stated | Phase 3 |
| Trials currently active | Not stated | 2 |
| Trial sponsors | Not stated | Boehringer Ingelheim |
| Published trials covered on its page | Not stated | 7 |
| Amounts studied in those trials | Not stated | NCT04153929: Survodutide up to 0.3, 0.9, 1.8 or 2.7 mg once weekly, or 1.2 or 1.8 mg twice weekly, against placebo and open label semaglutide up to 1.0 mg once weekly for 16 weeks NCT04667377: Survodutide 0.6, 2.4, 3.6 or 4.8 mg once weekly, or placebo, 1:1:1:1:1 for 46 weeks, 20 weeks of escalation then 26 weeks of maintenance NCT04771273: Survodutide 2.4, 4.8 or 6.0 mg once weekly, or placebo, 1:1:1:1 for 48 weeks, 24 weeks of rapid escalation then 24 weeks of maintenance As reported on the compound page. Amounts are not comparable between compounds. |
Full pages: 5-Amino-1MQ and Survodutide. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
